Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HHT add-on to DA/IA induction guided by day-5 peripheral residual blasts in de novo AML
ChiCTR-OPC-15006085Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of homoharringtonine in acute myeloid leukemia (AML), sponsored by Ruijin Hospital. Primary endpoints: Overall survival, Relapse-free survival and 1 more. Started Dec 2014; status: recruiting.
02
Drugs
homoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-OPC-15006085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-15006085.